Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGENDA: Genasense plus dacarbazine in advanced melanoma
NCT00518895Phase 3Completed
- Sponsor
- Genta Incorporated
- Start
- Jul 2007
- Primary completion
- May 2011
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Dacarbazine + Genasense with Dacarbazine + Placebo (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2007; status: completed.
02
Drugs
oblimersen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00518895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00518895.